Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Comment by sweatmanon Jun 19, 2013 11:13am
186 Views
Post# 21542462

RE: RE: news

RE: RE: news

You realize of course the entire tech report process is a long one. And special care *must* be taken here as the Company intends to do a lot of the work themselves...ie, bulk tonnage sampling. Before a report can be sanctioned as honest and true, there must be independent monitoring throughout every step of the process. After all, we do not want another case of geo's falling out of helicopters, what?  Is it a good buy at these levels? I would think so. At least that has been my call all along after that bloated financing at such a high price.  What I am keeping an eye  on of course is the *growing* dissent in the streets of the Brazilian cities, along with the collapsing worth of the Real and the inflation rate.  We should be keeping our fingers crossed that the cash-strapped government does not get silly with the mining regulations. I doubt that they will, as any usurious cash-grab will send the wrong signal to the internation exploration and mining community. So, anything around this price...$1.40 (or so) could be considered a gift.

Bullboard Posts